Drug
Lanoracopan clinical trials
Also written MY008211A.
- studies test it
- 11
- open now
- 6
- in phase 3
- 3
- first study started
- 2022
Keep track of what changes. Save the lanoracopan studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
11 studies that test it; most in 2024 (6)
| Year | Studies |
|---|---|
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 6 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 4
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 0
Wuhan Createrna Science and Technology Co., Ltd (11)
Studies
Open first, then newest update. How each study uses lanoracopan is read from its arms, and is right about nine times in ten.
Testing it · 11
- Study of Safety and Efficacy of MY008211A in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)Not yet recruitingPhase 2Wuhan Createrna Science and Technology Co., LtdNCT06134414Written as MY008211A tablets
- Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor TherapyRecruitingPhase 3Wuhan Createrna Science and Technology Co., LtdNCT06932744Written as MY008211A tablets
- Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody TreatmentRecruitingPhase 3Wuhan Createrna Science and Technology Co., LtdNCT06932471Written as MY008211A tablets
- Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal HemoglobinuriaRecruitingPhase 2/3Wuhan Createrna Science and Technology Co., LtdNCT06933914Written as MY008211A tablets
- Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)Not yet recruitingPhase 2Wuhan Createrna Science and Technology Co., LtdNCT06687174Written as MY008211A tablets
- To Evaluate the Effect of Single Oral Dose of MY008211A Tablets on QTc Interval in Healthy SubjectsNot yet recruitingPhase 1Wuhan Createrna Science and Technology Co., LtdNCT06543459Written as MY008211A tablets
- A Pharmacokinetic and Safety Study of MY008211A Tablets in Subjects With Impaired or Normal Hepatic FunctionCompletedPhase 1Wuhan Createrna Science and Technology Co., LtdNCT07625618Written as MY008211A tablets
- A Study of MY008211A in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)CompletedPhase 2Wuhan Createrna Science and Technology Co., LtdNCT06050226Written as MY008211A tablets
- A Study of Multiple Ascending Doses MY008211A in Healthy AdultsCompletedPhase 1Wuhan Createrna Science and Technology Co., LtdNCT05828472Written as MY008211A tablets
- A Study of Single-dose MY008211A in Healthy AdultsCompletedPhase 1Wuhan Createrna Science and Technology Co., LtdNCT05642585Written as MY008211A tablets
- Effect of Food on Pharmacokinetics of MY008211A Tablets in Healthy Adult SubjectsCompletedPhase 1Wuhan Createrna Science and Technology Co., LtdNCT05828485Written as MY008211A tablets
Codes
What other systems call lanoracopan · ClinicalTrials.gg INT018552
- UNII (FDA) Y5UN7AE8SFLANORACOPANOne source FDA
- NCI Thesaurus C215276LanoracopanOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | Y5UN7AE8SF | LANORACOPAN | One source FDA |
| NCI Thesaurus | C215276 | Lanoracopan | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.